Clinical trials in Ulm – page 22

574 clinical trials in Ulm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Ulm at a glance

574

clinical trials

Research sites2

Quick filters

574 trials in Ulm

Open in trial search

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:ABBV-8736
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Beclometasone Dipropionate
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Ioflupane (123I)
Sponsor:Biohaven Therapeutics Ltd.

Contact Research Centre

Ischaemic stroke

Not yet recruiting

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo

Enhanced dual antiplatelet therapy with clopidogrel and acetylsalicylic acid for secondary prevention in patients with mild ischemic stroke

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Technische Universitaet Dresden

Contact Research Centre

Crohn's disease

Not yet recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ORG-129
Sponsor:Agomab Spain S.L.U.

Contact Research Centre

Ovarian cancer

Not yet recruiting

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Chronic graft versus host disease

Not yet recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Neoplasm

Not yet recruiting

Study of sacituzumab govitecan versus investigator’s choice drug combination in patients with cancer of unknown primary after platinum‑based chemotherapy failure

Registered drugNo placebo

Study of sacituzumab govitecan versus investigator’s choice drug combination in patients with cancer of unknown primary after platinum‑based chemotherapy failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Posaconazole
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Ulm

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, acute myeloid leukemia, and various types of lymphomas. Studies are evaluating novel combination therapies and targeted treatments for patients with specific genetic mutations.

Metastatic Colorectal Cancer Treatment
B-Cell Lymphoma Therapies
Advanced Breast Cancer Studies

Multiple trials investigating innovative treatment approaches for blood cancers and solid tumors.

02 Neurological Disorders

Clinical research targeting multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. Studies are exploring new therapeutic agents and diagnostic tools.

Early-Stage Alzheimer's Treatment
Progressive MS Therapies
ALS Gene-Targeted Treatments

Innovative approaches in neurodegenerative disease management and treatment.

03 Autoimmune Conditions

Comprehensive studies on inflammatory bowel diseases, rheumatoid arthritis, and Sjögren's disease. Research focuses on novel biological therapies and long-term treatment options.

Crohn's Disease Treatments
Ulcerative Colitis Management
Autoimmune Disorder Therapies

Advanced therapeutic approaches for chronic inflammatory conditions.

Back to Germany All countries